Neurological

Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

topics » Movement disorders

The Food and Drug Administration has granted Orphan Drug designation to elamipretide for the treatment of Friedreich’s ataxia.

Friedreich ataxia is a rare genetic disease caused by mutations in the FXN gene resulting in a relative deficiency of frataxin, and leading to mitochondrial iron accumulation and oxidative stress. The disease is typically characterized by progressive decline in visual function, dysarthria, cardiomyopathy, characteristic foot deformities, and scoliosis.

Elamipretide is a peptide compound designed to readily penetrate cell membranes targeting the inner mitochondrial membrane where it binds reversibly to cardiolipin. In preclinical studies, elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.

Continue Reading

The Company has started evaluating the safety, visual function, and cardiac function of 2 doses of elamipretide in patients with Friedreich ataxia in a phase 2a investigator-initiated study (ClinicalTrials.gov Identifier: NCT05168774).

“We are pleased that the FDA has recognized the high unmet need for innovative treatments for Friedreich’s ataxia,” said CEO Reenie McCarthy. “We are delighted to be working closely with Dr. Lynch and the Children’s Hospital of Pennsylvania to evaluate elamipretide as a potential treatment for the progressive visual dysfunction and cardiomyopathy that affects visual quality of life and lifespan for individuals affected with this disease.”

The FDA’s Orphan Drug designation is granted to medicines intended to treat or prevent rare diseases or disorders that affect fewer than 200,000 individuals.

References

  1. Stealth BioTherapeutics receives Orphan Drug designation from FDA for elamipretide for the treatment of Friedreich’s ataxia. release. Stealth BioTherapeutics Inc. Accessed March 28, 2022. https://www.prnewswire.com/news-releases/stealth-biotherapeutics-receives-orphan-drug-designation-from-fda-for-elamipretide-for-the-treatment- of-friedreichs-ataxia-301511115.html
  2. Programs & Pipeline: Pipeline. Stealth BioTherapeutics Inc. Accessed March 28, 2022. https://www.stealthbt.com/programs-pipeline/
  3. Rare Disease Database: Friedreich’s Ataxia. National Organization for Rare Disorders, Inc. Accessed March 28, 2022. https://rarediseases.org/rare-diseases/friedreichs-ataxia/

This article originally appeared on MPR

Topics:

Ataxia Genetic Disease Movement Disorders

Want to read more?

Please login or register first to view this content.

Login register

Open

Next post in Movement Disorders

Close


Close more info about Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

Loading…


Close more info about Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

Loading…


Close more info about Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

Loading…


Close more info about Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

Loading…

Want to view more content from Neurology Advisor?

Register now at no charge to access unlimited clinical news with personalized daily picks for youfull-length features, case studies, conference coverage, and more.

{{login button}} {{register button}}

Want to read more?

Please login or register first to view this content.

Login register

Related Articles